β2‐adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma

BACKGROUND: Vascular endothelial growth factor (VEGF) was initially known as vascular permeability factor and identified as a driver of tumour angiogenesis. Recently, its role in supporting an immunosuppressive tumour microenvironment was demonstrated, and anti‐VEGF treatment combined with immune ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuster, Cornelia, Akslen, Lars A., Straume, Oddbjørn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524038/
https://www.ncbi.nlm.nih.gov/pubmed/37551424
http://dx.doi.org/10.1002/cam4.6424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524038/
https://www.ncbi.nlm.nih.gov/pubmed/37551424
http://dx.doi.org/10.1002/cam4.6424

Ejemplares similares